Key facts
- This page summarizes Ken Kobayashi's Form 4 filing for Pyxis Oncology, Inc. (PYXS).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 29 Dec 2023, 16:33.
Ken Kobayashi - 29 Dec 2023 Form 4 Insider Report for Pyxis Oncology, Inc. (PYXS)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- PYXS
- Reported as of
- 29 Dec 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 29 Dec 2023, 16:33:36 UTC
- Prior SEC filing
- 06 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Pamela Connealy, Attorney-in-Fact for Ken Kobayashi
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Ken Kobayashi filed Form 4 for Pyxis Oncology, Inc. (PYXS) on 29 Dec 2023.
Change
- Previous filing in this sequence was filed on 06 Dec 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PYXS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +443,514
- Change %
- Price
- $0.000000
- Shares after
- 443,514
- Date
- 29 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 443,514
- Exercise price
- $1.80
- Footnotes
- F1
PYXS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +110,878
- Change %
- Price
- $0.000000
- Shares after
- 110,878
- Date
- 29 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 110,878
- Exercise price
- $1.80
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares subject to this option will vest over four years, with 25% vesting on November 27, 2024 and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates.
Footnote F2
The shares subject to this option will vest upon the achievement of certain clinical milestones related to data disclosure for PYX-201.